Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform standing and nary terms target. The expert stated dabogratinib could “achieve the CR barroom for LR IR NMIBC” portion remaining “on the fence” pending information de-risking.

On May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) reported Q1 results, advancing its “dabogratinib 3×3” strategy, dosing the archetypal LG-UTUC diligent successful SURF303, and targeting archetypal results successful 2027. Cash stood astatine $383.5 million, backing operations into 2H 2028.

The institution posted a nett nonaccomplishment of $39.3 cardinal from $28.1 cardinal a twelvemonth earlier and raised R&D expenses to $33.5 million.

Photo by National Cancer Institute connected Unsplash

CEO Todd Harris said the steadfast “continues to beforehand with dependable progress,” flagging aggregate information readouts successful 2026.

Chief Medical Officer Doug Warner noted dabogratinib whitethorn “represent a meaningful shift” successful treatment, pointing to the Phase 2 studies crossed 3 indications.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is simply a precision oncology steadfast that develops purpose-built treatments to flooded tumor absorption and amended crab patients’ outcomes.

While we admit the imaginable of TYRA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.